Plus, news about Basilea, BARDA, Inventiva and CTTQ:
Recursion buys full rights to oral drug: The AI-driven biotech, which recently restructured, acquired the full rights to REV102, an ...
↧
Recursion takes full rights to rare genetic disorder drug; CStone out-licenses cancer drug in Europe
↧